

v. 114, no. 13 (Sept. 24 2009)  
General Collection  
W1 BL661  
2009-10-16 10:24:04

# blood

JOURNAL OF  
THE AMERICAN  
SOCIETY OF  
HEMATOLOGY

VOLUME 114  
NUMBER 13  
24 SEPTEMBER 2009

- Allogeneic transplantation for CLL (p 2581)
- An anti-KIR antibody to augment NK-mediated killing (p 2667)
- Duffy-null leukopenic patients with HIV have a survival advantage (p 2783)
- Selective depletion of alloreactive T cells by heat shock protein targeting (p 2829)
- Hyperfunctional C3 convertase and atypical HUS (p 2837)
- Cover: Gene therapy safety (p 2921)



PROPERTY OF THE  
NATIONAL  
LIBRARY OF  
MEDICINE

Genome & Co. v. Univ. of Chicago  
PGR2019-00002  
UNIV. CHICAGO EX. 2009



*Blood, Journal of The American Society of Hematology* (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly every Thursday, except for the last week in December, (52 times weekly), plus the ASH annual meeting abstracts in November, by the American Society of Hematology (ASH), 1900 M Street, NW, Suite 200, Washington, DC 20036. Printed in the United States of America. Periodicals postage paid at Washington, DC, and additional mailing offices.

**Postmaster:** Send change-of-address information to *Blood, Journal of the American Society of Hematology*, Subscription Office, 1900 M Street, NW, Suite 200, Washington, DC 20036.

**Canadian regulations:** Publications Mail Agreement No: 40038947. Return undeliverable Canadian addresses to: Circulation Dept. or DPGM, 4960-2 Walker Road, Windsor, ON N9A 6J3.

### Manuscript submissions

Consult the Author Guide printed in each issue of *Blood* (and posted on the web site at [www.bloodjournal.org](http://www.bloodjournal.org)) before submitting your manuscript online at <http://submit.bloodjournal.org>.

### 2009 subscription rates

US Institution, Online plus Print: \$1,350 (Tier 2); \$1,440 (Tier 3)

US Institution, Online Only: \$1,220 (Tier 2); \$1,310 (Tier 3)

International Institution, Online plus Print: \$1,570 (Tier 2); \$1,660 (Tier 3)

International Institution, Online Only: \$1,220 (Tier 2); \$1,310 (Tier 3)

US Individual, Online plus Print: \$800

International Individual, Online plus Print: \$1,020

\*All issues shipped via expedited service at no additional charge.

**Price for single/back issues:** \$35 (US)/\$40 (international). Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability.

**Pay-per-view:** Full-text online access to all articles is free one year after publication. Nonsubscribers may purchase 24-hour access to the full text of any article published in the preceding 12 months through the pay-per-view option on the *Blood* website.

### Subscription information, claims, and changes of address

**Customer service for subscribers: 1-866-328-8560 (US and Canada); 1-202-292-0280 (outside US and Canada); fax: 1-202-292-6010; e-mail: [bloodsubs@hematology.org](mailto:bloodsubs@hematology.org).** Correspondence regarding subscriptions and changes of address should be addressed to *Blood* Journal Subscription Office, 1900 M Street, NW, Suite 200, Washington, DC 20036. Checks should be made payable to "Blood Subscriptions."

ASH Members should send their change-of-address information to the ASH Membership Department, 1900 M Street, NW, Suite 200, Washington, DC 20036.

All change-of-address notices should be sent at least 6 weeks before the first issue is to be mailed to the new address. Provide both old and new addresses.

**Claims:** Claims must be submitted within 4 months of the publication date (6 months for international subscribers).

### Internet

**Blood Home Page:** [www.bloodjournal.org](http://www.bloodjournal.org).

**ASH Home Page:** [www.hematology.org](http://www.hematology.org).

**Manuscript Submission:** [submit.bloodjournal.org](http://submit.bloodjournal.org).

### Copyright

Copyright © 2009 by The American Society of Hematology. All rights reserved. No part of this publication may be reproduced (see exception below), stored in a retrieval system, translated, or transmitted in any form or by any means now or hereafter known, electronic or mechanical, without permission in writing from the Publisher, The American Society of Hematology. Address for correspondence: Blood Publishing Office, 1900 M Street, NW, Suite 200, Washington, DC 20036. Important notice: Authors retain certain nonexclusive copyrights. For further information on rights and permissions, see [www.bloodjournal.org/misc/rights.shtml](http://www.bloodjournal.org/misc/rights.shtml).

The copyright owner consents that copies of articles may be made for personal or internal use, or for the personal or internal use of specific clients, for those registered with the Copyright Clearance Center, Inc (222 Rosewood Drive, Danvers, MA 01923; (978) 750-8400; [www.copyright.com](http://www.copyright.com)). This consent is given on the condition that the copier pay the stated per-copy fees through the Copyright Clearance Center, Inc, for copying beyond that permitted by Sections 107 and 108 of the US Copyright Law (Fair Use). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. For those kinds of purposes, permission must be sought from the Publisher (see above).

### Advertising representation

To place orders for product advertisements, classifieds, or commercial reprints, contact Kevin Dunn, Cunningham Associates, 180 Old Tappan Road, Old Tappan, NJ 07675. Telephone: 201-767-4170; fax: 201-767-8065; e-mail: [kdunn@cunnasso.com](mailto:kdunn@cunnasso.com).

### Disclaimer

The ideas and opinions expressed in *Blood* do not necessarily reflect those of The American Society of Hematology or the Editors of *Blood*. Publication of an advertisement or other product mention in *Blood* should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. The American Society of Hematology does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

### Indexing & abstracting

*Blood* is indexed and abstracted by Index Medicus, Excerpta Medica, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, SCISEARCH, Automatic Subject Citation Alert, ISI/BIOMED, and BIOSIS.



**COVER FIGURE**

It is unclear how neutrophils control *Aspergillus* species in healthy persons. Due to their large size, *Aspergillus* hyphae (red) cannot be phagocytosed by neutrophils (green). Bianchi et al show in this issue that recently discovered NADPH oxidase–dependent microbicidal pathways through neutrophil extracellular traps (NETs) are efficient against *Aspergillus* conidia and hyphae in vitro, and that restoration of NET formation by gene therapy of NADPH oxidase–deficient X-linked chronic granulomatous disease aided clearing severe invasive *Aspergillus nidulans* infection in vivo, underlining the role of functional NADPH oxidase in NET formation and antifungal activity. See the article by Bianchi et al on page 2619.

**INSIDE BLOOD**

- 2567 **NK antibody therapy: KIR-ative intent**  
N. Shah and E. J. Shpall
- 2568 **“Tax-ing” the cancer stem cell**  
G. Feuer
- 2569 **Missteps in “tango” for epigenome targeting**  
K. D. Robertson and K. N. Bhalla
- 2570 **HIV: getting to the heart of DARCness**  
R. J. B. Nibbs
- 2571 **Platelet integrin signaling: wherefore art thou?**  
A. A. Schmaier and M. L. Kahn
- 2572 **Super factor B-gets atypical HUS**  
E. M. Conway

**PERSPECTIVE**

- 2575 **Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment**  
M. A. Sekeres and D. P. Steensma

**REVIEW ARTICLE**

- 2581 **Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?**  
J. Delgado, D. W. Milligan, and P. Dreger

**CLINICAL TRIALS AND  
OBSERVATIONS**

- 2589 **Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, *TP53* mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial**  
T. Zenz, S. Häbe, T. Denzel, J. Mohr, D. Winkler, A. Bühler, A. Sarno, S. Groner, D. Mertens, R. Busch, M. Hallek, H. Döhner, and S. Stilgenbauer

- 2598 **Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib**  
R. D. Press, S. G. Willis, J. Laudadio, M. J. Mauro, and M. W. N. Deininger
- 2606 **Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34<sup>+</sup> cell dose**  
M. A. Pulsipher, P. Chitphakdithai, B. R. Logan, S. F. Leitman, P. Anderlini, J. P. Klein, M. M. Horowitz, J. P. Miller, R. J. King, and D. L. Confer
- 2617 **Brief report The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma**  
C. E. Chee, S. Kumar, D. R. Larson, R. A. Kyle, A. Dispenzieri, M. A. Gertz, C. L. Colby, and S. V. Rajkumar

---

#### GENE THERAPY

- 2619 **Brief report Restoration of NET formation by gene therapy in CGD controls aspergillosis**  
M. Bianchi, A. Hakkim, V. Brinkmann, U. Siler, R. A. Seger, A. Zychlinsky, and J. Reichenbach

---

#### IMMUNOBIOLOGY

- 2623 **Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon- $\beta$**   
Y. Gao, B. Majchrzak-Kita, E. N. Fish, and J. L. Gommerman
- 2632 **Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties**  
M. François, R. Romieu-Mourez, S. Stock-Martineau, M.-N. Boivin, J. L. Bramson, and J. Galipeau
- 2639 **Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation**  
S. Piconese, G. Gri, C. Tripodo, S. Musio, A. Gorzanelli, B. Frossi, R. Pedotti, C. E. Pucillo, and M. P. Colombo
- 2649 **Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6**  
K. D. Dyer, C. M. Percopo, E. R. Fischer, S. J. Gabryszewski, and H. F. Rosenberg
- 2657 **Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors**  
Y. T. Bryceson, H.-G. Ljunggren, and E. O. Long
- 2667 **Preclinical characterization of I-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells**  
F. Romagné, P. André, P. Spee, S. Zahn, N. Anfossi, L. Gauthier, M. Capanni, L. Ruggeri, D. M. Benson Jr, B. W. Blaser, M. D. Chiesa, A. Moretta, E. Vivier, M. A. Caligiuri, A. Velardi, and N. Wagtmann



**LYMPHOID  
NEOPLASIA**

- 2678 **Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia**  
R. M. A. Linger, D. DeRyckere, L. Brandão, K. K. Sawczyn, K. M. Jacobsen, X. Liang, A. K. Keating, and D. K. Graham
- 2688 **Deregulated expression of cytokine receptor gene, *CRLF2*, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia**  
L. J. Russell, M. Capasso, I. Vater, T. Akasaka, O. A. Bernard, M. J. Calasanz, T. Chandrasekaran, E. Chapiro, S. Gesk, M. Griffiths, D. S. Guttery, C. Haferlach, L. Harder, O. Heidenreich, J. Irving, L. Kearney, F. Nguyen-Khac, L. Machado, L. Minto, A. Majid, A. V. Moorman, H. Morrison, V. Rand, J. C. Strefford, C. Schwab, H. Tönnies, M. J. S. Dyer, R. Siebert, and C. J. Harrison
- 2699 **Aurora kinase A is a target of Wnt/ $\beta$ -catenin involved in multiple myeloma disease progression**  
J. Dutta-Simmons, Y. Zhang, G. Gorgun, M. Gatt, M. Mani, T. Hideshima, K. Takada, N. E. Carlson, D. E. Carrasco, Y.-T. Tai, N. Raje, A. G. Letai, K. C. Anderson, and D. R. Carrasco
- 2709 **Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma**  
J. Yamazaki, T. Mizukami, K. Takizawa, M. Kuramitsu, H. Momose, A. Masumi, Y. Ami, H. Hasegawa, W. W. Hall, H. Tsujimoto, I. Hamaguchi, and K. Yamaguchi
- 2721 **Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma**  
D. Dornan, F. Bennett, Y. Chen, M. Dennis, D. Eaton, K. Elkins, D. French, M. A. T. Go, A. Jack, J. R. Junutula, H. Koeppen, J. Lau, J. McBride, A. Rawstron, X. Shi, N. Yu, S.-F. Yu, P. Yue, B. Zheng, A. Ebens, and A. G. Polson
- 2730 **Brief report A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma**  
M. P. Purdue, Q. Lan, O. Martinez-Maza, M. M. Oken, W. Hocking, W.-Y. Huang, D. Baris, B. Conde, and N. Rothman

**MYELOID  
NEOPLASIA**

- 2733 **Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells**  
W. Fiskus, Y. Wang, A. Sreekumar, K. M. Buckley, H. Shi, A. Jillella, C. Ustun, R. Rao, P. Fernandez, J. Chen, R. Balusu, S. Koul, P. Atadja, V. E. Marquez, and K. N. Bhalla
- 2744 **RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia**  
H. Edwards, C. Xie, K. M. LaFiura, A. A. Dombkowski, S. A. Buck, J. L. Boerner, J. W. Taub, L. H. Matherly, and Y. Ge
- 2753 **Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome**  
D. C. Cabelof, H. V. Patel, Q. Chen, H. van Remmen, L. H. Matherly, Y. Ge, and J. W. Taub

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.